Alnylam Pharmaceuticals, Inc. (ALNY)

AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Analysts

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook

Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture

Arizona State Retirement System Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Concurrent Investment Advisors LLC Acquires 6,576 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Alnylam to Webcast Presentations at Upcoming September Investor Conferences